GSK'S INNOVATIVE ADJUVANT IN CANDIDATE HPV VACCINE (CERVARIXTM) INDUCES STRONGER & SUSTAINED IMMUNE RESPONSE COMPARED TO CONVENTIONAL ADJUVANT

The immune response against the virus that causes cervical cancer is stronger and sustained following vaccination with GlaxoSmithKline's (GSK) candidate HPV vaccine formulated with the innovative AS04 adjuvant compared to using the same vaccine formulated with a conventional aluminium salt adjuvant.
Medical News Today